Furthermore, DC646 demonstrates the ability to alleviate symptoms related to metabolic dysfunction-associated steatohepatitis (MASH) in mice, relying on its selective inhibition of intestinal FXR. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.